Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases. The company’s lead drug candidate, SLV213, is an orally available small molecule novel antiviral therapy with activity against a broad range of viruses that threaten global health, including SARS-CoV-2, the virus causing COVID-19. In addition, SLV213 has activity against Ebola and Nipah viruses and has completed preclinical development as a potential therapy against Chagas disease. Selva is headquartered in San Diego.
Company Details
- Employees
- 4
- Address
- San Diego, Ca, Us
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- selvarx.com
- HQ
- San Diego, CA
Selva Therapeutics Questions
Selva Therapeutics's website is selvarx.com
Selva Therapeutics's LinkedIn profile is https://www.linkedin.com/company/selva-therapeutics
Selva Therapeutics has
4 employees.
View email and phone details for 4
employees at Selva Therapeutics.
Selva Therapeutics's industry is
Pharmaceutical Manufacturing
Selva Therapeutics's top competitors are
Venquis Therapeutics,
Trestle Biotherapeutics,
Vasa Therapeutics,
Xcmr,
Senhwa Biosciences, Inc.,
Idbiologics, Inc.,
Sydnexis,
Splash Pharmaceuticals,
Endure Biotherapeutics,
Sinopia Biosciences.
Selva Therapeutics's categories are Pharmaceutical Manufacturing
